We are live on ! Find out more
BCTX icon

BriaCell Therapeutics

23 hedge funds and large institutions have $14.6M invested in BriaCell Therapeutics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,793% more call options, than puts

Call options by funds: $4.6M | Put options by funds: $243K

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

28% more funds holding

Funds holding: 18 → 23 (+5)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.38% less ownership

Funds ownership: 16.98% → 15.6% (-1.4%)

59% less capital inflows, than outflows

Capital inflows: $769K | Capital outflows: $1.86M

Holders
23
Holders Change
+5
Holders Change %
+27.78%
% of All Funds
0.33%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
6
Increased
7
Reduced
5
Closed
1
Calls
$4.6​M
Puts
$243​K
Net Calls
+$4.36​M
Net Calls Change
+$414​K

BCTX Hedge Fund Activity: Q4 2023 in Review

23 of the 6,880 institutional investors tracked by Wall St. Rank reported a position in BriaCell Therapeutics (BCTX) for Q4 2023, worth a combined $14.6M — down 14% from $17M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new BCTX positions and 1 closed out — a net gain of 5 holders — while 7 added to existing stakes and 5 trimmed.

The largest buyer was Marex Group, opening a new position worth an estimated $144K. The largest seller was Wasatch Advisors, cutting an estimated $1.18M.

  • 23 institutional investors held BriaCell Therapeutics (BCTX) as of Q4 2023, up from 18 in Q3 2023.
  • Funds reported $14.6M of BriaCell Therapeutics stock for Q4 2023, down 14% quarter-over-quarter.
  • 6 funds opened new BriaCell Therapeutics positions in Q4 2023 and 1 closed out, a net change of +5 holders.
  • The largest BriaCell Therapeutics buyer in Q4 2023 was Marex Group, an estimated $144K added.
  • The largest BriaCell Therapeutics seller in Q4 2023 was Wasatch Advisors, an estimated $1.18M sold.

Based on aggregated 13F filings for Q4 2023.